By Gina Shaw
The Centers for Medicare & Medicaid Services (CMS) finalized its Medicare coverage policy for the controversial Alzheimer’s disease drug aducanumab (Aduhelm, Biogen) on April 7, 2022. As in the initial plan released in March, aducanumab will be covered for Medicare recipients under the “coverage with evidence development” (CED) guidance, meaning the drug will only be covered in the setting of a clinical trial.
However, the final proposal contains several